RFS, OS, and melanoma‐specific survival (MSS), and response to subsequent treatment in 589 stage III patients (232 BRAF‐mutated) receiving adjuvant PD‐1 antibodies (n = 479) or targeted therapy (n = 110) have been reported. Here, BRAF is linked to melanoma.